



SYMPTOM BENEFIT Working Group, Endometrial Cancer

Brainstorming Session

Saturday, December 1, 2012, 1:00pm – 5:30pm

Utrecht Room, Holiday Inn, Leiden

AGENDA

Co-Chairs: Florence Joly and Jessica McAlpine

- 1:00-1:15pm Welcome & Introductions - COI Declaration
New format, goals of meeting and review of the agenda
- 1:15-1:45pm Speaker: E Greimel
- *QOL tools/evaluations in EM cancer: where are we now?
 - *EN24- development, validation, trials currently using, pros/cons, deficiencies and strategies to overcome, alternatives (i.e., FACT-En)
 - *New options for commonly underreported aspects in EM: sexual health, advanced stage/high risk disease
- 1:45-2:25pm Speaker: R Nout
- *Review of success and challenges in QOL trials in EM cancer in the past, next steps
 - *Review of studies on long term survivors in EM cancer (an/or similar work in other cancer receiving pelvic RT etc). The latter part of this session may be interactive and involve reflection of circulated list of current trials in EM including survivorship, weight loss, exercise interventions... Is there room for improvement? Unanswered questions?

2:25pm

BREAK

2: 45pm

Group Discussion: Can we agree upon an acceptable list of options of QOL tools in EM cancer that we recommend should be part of EVERY trial? May be recommended to add on to existing trials, or part of planning in future. Compose list, disseminate to your cancer groups, offer study coordinators the opportunity for GCIG SB collaborators/panel to review QOL portions of upcoming trials.

3:30pm

Group Discussion: At present, what do we agree are the major deficiencies in our knowledge of symptoms, needs, greatest impact on QOL in women with EM cancer? What is being missed/gaps in data collection in current trials? Suggested direction may be **addressing the current lack of data on QOL for women with advanced stage disease and high risk subtypes of EM cancer**. What is being included in the 3 major advanced stage EM trials upcoming? How might we improve these?

4:15pm

Group Discussion: Generation of a state of the art QOL in EM cancer position paper from the GCIG with authorship from all present and others interested in contributing. Paper to include summary of current trials, successes/recaps of what has been achieved, development of tools and agreed upon standards/options, deficiencies and gaps with strategies to address, new trials going forward and new specific areas: advanced disease, obesity, sexual health, diabetes, elderly, etc.

5:30pm

Adjourn